Generation Bio Co. (NASDAQ:GBIO) Sees Significant Growth in Short Interest

Generation Bio Co. (NASDAQ:GBIO) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 7,952 shares, an increase of 284.5% from the January 15th total of 2,068 shares. Based on an average daily volume of 127,651 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the shares of the company are sold short. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 127,651 shares, the short-interest ratio is presently 0.1 days.

Generation Bio Stock Performance

GBIO remained flat at $5.34 during trading on Wednesday. The business’s fifty day simple moving average is $5.52 and its 200-day simple moving average is $5.62. The firm has a market capitalization of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05. Generation Bio has a 12 month low of $3.00 and a 12 month high of $8.20.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and cut their price target for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th. Wedbush set a $5.50 price target on shares of Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Zacks Research raised Generation Bio to a “hold” rating in a report on Monday, January 26th. Finally, Citigroup restated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Generation Bio currently has an average rating of “Hold” and a consensus target price of $8.88.

Hedge Funds Weigh In On Generation Bio

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new stake in shares of Generation Bio during the first quarter valued at $36,000. Marshall Wace LLP purchased a new stake in Generation Bio during the second quarter valued at about $37,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Generation Bio in the second quarter worth approximately $47,000. Shay Capital LLC acquired a new stake in shares of Generation Bio during the third quarter valued at approximately $64,000. Finally, ADAR1 Capital Management LLC purchased a new position in Generation Bio during the 3rd quarter worth approximately $136,000. Institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.